SCHEMBL25880411

SCHEMBL25880411

c1ccc(-c2ccc3c4c2c2cc(-c5ccc6ccccc6c5)ccc2n4c2ccc(-c4ccccc4)c4c5cc(-c6ccc7ccccc7c6)ccc5n3c42)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 2/20 0.38
HSD17B2 P37059 2/20 0.38
ESR1 P03372 3/20 0.37
ESR2 Q92731 3/20 0.37
GSTP1 P09211 1/20 0.37
CYP17A1 P05093 1/20 0.36
CYP19A1 P11511 1/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
AKR1C3 P42330 2/20 0.36
AKR1C2 P52895 2/20 0.36
ALOX5 P09917 1/20 0.36
NR3C1 P04150 1/20 0.35
CYP1A1 P04798 1/20 0.35
CYP1B1 Q16678 1/20 0.35
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34
CYP1A2 P05177 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25880425 0.84 NR3C1 (0.35) ALOX5NR3C1SMN1; SMN2MEN1KMT2A
SCHEMBL25880422 0.84 ALK (0.35) ESR1NR3C1SMN1; SMN2MEN1KMT2A
SCHEMBL25880419 0.81 MEN1 (0.34) ALOX5SMN1; SMN2MEN1KMT2AHSD17B10
SCHEMBL25880354 0.78 HSD17B10 (0.41) KDM4EALDH1A1MEN1KMT2AHSD17B10
SCHEMBL25880531 0.77 MEN1 (0.37) NR3C1KDM4EALDH1A1MEN1KMT2A
SCHEMBL15460068 0.77 HSD17B1 (0.44) HSD17B1HSD17B2ESR1ESR2GSTP1
SCHEMBL25880521 0.75 KMT2A (0.37) KDM4EALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL25880382 0.75 HSD17B10 (0.36) NR3C1KDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL24601471 0.74 TSPO (0.39) ESR1ESR2ALOX5NR3C1KDM4E
SCHEMBL15460075 0.74 HSD17B1 (0.47) HSD17B1HSD17B2ESR1ESR2GSTP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230240135-A1 HETEROCYLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE HETEROCYCLIC COMPOUND AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2023-07-27 US disclosed
US-20230240135-A1 HETEROCYLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE HETEROCYCLIC COMPOUND AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230240135-A1 HETEROCYLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE HETEROCYCLIC COMPOUND AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE CRY1, LAGE3, NQO1 HSD17B1 1318/4885HSD17B2 891/4885ESR1 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.